Now, scientists at ETH Zurich, in collaboration with Balgrist University Hospital, have created a fast and promising new test ...

A rare syndrome linked to purple urine reveals surprising insights into bacterial colonisation, metabolism, and risks for ...

Blujepa, the first new oral UTI antibiotic in 30 years, offers hope against antibiotic-resistant infections, improving ...

Gepotidacin is an oral, first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA replication by blocking 2 different type II topoisomerase enzymes.

For 25 hours straight, Cory Booker stood on the Senate floor delivering the longest speech in the chamber’s history without ...

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on ...

WFS1 and CISD2 regulate IP3R activity through their interaction. In Wolfram syndrome, their dysfunction reduces cytosolic calcium levels, resulting in diabetes. WFS1 and CISD2 bind to IP3R and ...

Antibiotic resistance is a growing threat. Empa's innovative sensors offer rapid detection of resistant pathogens, improving ...

Jyong Biotech Ltd. (Revived IPO) (MENS) expects to raise $22 million in an IPO on the week of April 7th, IPO Scoop reports.

With two dogs at opposite ends of the age spectrum, whole-body wellness is a big concern in our household. We want our ...

The novel antibiotic class could be active against the vast majority of multidrug-resistant Enterobacterales infections.

Jyong Biotech Ltd. (Revived IPO) (MENS) expects to raise $22 million in an initial public offering (IPO) on the week of April 7th, IPO Scoop reports. The company plans to issue 2,700,000 shares at $7.